You can buy or sell SGEN and other stocks, options, ETFs, and crypto commission-free!
Seattle Genetics, Inc. Common Stock, also called Seattle Genetics, is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Read More Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
52 Week High
52 Week Low
Associated PressMar 21
Global Hodgkin’s Lymphoma Drugs Market Outlook, 2019 to 2023 - Bristol-Myers Squibb Company, Merck & Co, Ono Pharmaceutical Co, Pfizer, and Seattle Genetics are Dominating - ResearchAndMarkets.com
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. Global Hodgkin’s Lymphoma Drugs Market Outlook, 2019 to 2023 - Bristol-Myers Squibb Company, Merck & Co, Ono Pharmaceutical Co, Pfizer, and Seattle Genetics are Dominating - ResearchAndMarkets.com This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. DUBLIN--(BUSINESS WIRE)--Mar 2...
Yahoo FinanceMar 9
Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. A month has gone by since the last earnings report for Seattle Genetics (SGEN). Shares have lost about 6.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Seattle Genetics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick loo...
Simply Wall StMar 7
If You Had Bought Seattle Genetics Shares Three Years Ago You’d Have Made 113%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more than 100%. To wit, the Seattle Genetics, Inc. (NASDAQ:SGEN) share price has flown 113% in the last three years. That sort of return is as solid as granite. It’s also good to see the share price up 12% over the last quarter. See our latest analysis for Seattle Genetics Seattle Genetics isn’t currently profitable, ...
Expected Apr 25, After Hours